2008 NSTI Nanotechnology Conference and Trade Show - Nanotech 2008 - 11th Annual

Partnering Events:

TechConnect Summit
Clean Technology 2008

Encapsulation and Extended release of Anti-cancer Anastrozole by Stealth Nanoparticles

K. Sarkar, H. Yang
Virginia Commonwealth University, US

anastrozole, PAMAM dendrimer, PEG, drug delivery, nanomedicine, nanoparticle, controlled release

Anastrozole is used to treat breast cancer in postmenopausal women that are estrogen-receptor positive. Anastrozole increases plasma testosterone concentrations by blocking the conversion of androgens to estrogens. The current problems with oral-pill delivery of anti-cancer drugs, like Anastrozole, are that that they have 1) low solubility (0.5 mg/ml) in water, 2) short half-life of 50 hours, and 3) untargeted release. In order to address these issues, we designed a novel polymer-based drug delivery system using PAMAM dendrimers Generations 3 and 4 (G3 and G4) conjugated with PEG6000 chains that can encapsulate Anastrozole and release it inside the body. First, the PEG6000 chain modified to form PEG 4-Nitrophenyl Carbonate. Using G3 and G4 PAMAM dendrimers, the PEG6000 chains were attached to the outside. Next, saturated Anastrozole solution was encapsulated into 5 mg, 10 mg, and 20 mg of PAMAM G3 + PEG6000 complex and PAMAM G4 + PEG6000 complex. After successful drug encapsulation, release kinetics was done using UV-visible spectrometry. With the decrease in total absorbance over time, we demonstrated release of encapsulated Anastrozole. Finally, the PEG chains and the arms of the dendrimers can be used to conjugate ligand for targeted drug delivery. Hence, this system stands to be a promising solution for treating breast cancer

Nanotech 2008 Conference Program Abstract